Literature DB >> 29190164

Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group.

Deepa Bhojwani1, Michael J Burke2, Terzah Horton3, David S Ziegler4, Maria Luisa Sulis5, Kirk R Schultz6, Alan Wayne1, Shai Izraeli7, Bill H Chang8.   

Abstract

During the 2016 Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium investigators' meeting (Los Angeles, CA), a Biology Working Group was established to support the consortium's mission of developing innovative therapies for currently incurable childhood leukemias and lymphomas. The charge of the Biology Working Group was to address how TACL could advance biological investigations of pediatric relapsed/refractory hematologic malignancies while undertaking forward-looking therapeutic trials. To this end, the TACL Biology Committee was established to provide the scientific platform needed to further develop preclinical and translational studies that will advance the understanding and treatment of relapsed and refractory disease. The Biology Committee will focus on ensuring state-of-the-art studies that address biological components of early phase clinical trials, and developing a central biology bank of materials from these early phase trials for interrogations into the mechanisms of disease resistance.

Entities:  

Keywords:  Leukemia; biology; epigenomics; genomics; relapse

Mesh：

Year:  2017        PMID： 29190164      PMCID： PMC6191173          DOI： 10.1080/08880018.2017.1395937

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN： 0888-0018            Impact factor:   1.969


  44 in total

1.  Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.

Authors:  Laura E Hogan; Julia A Meyer; Jun Yang; Jinhua Wang; Nicholas Wong; Wenjian Yang; Gregory Condos; Stephen P Hunger; Elizabeth Raetz; Richard Saffery; Mary V Relling; Deepa Bhojwani; Debra J Morrison; William L Carroll
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

2.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.

Authors:  Gail M Gauvreau; Paul M O'Byrne; Louis-Philippe Boulet; Ying Wang; Donald Cockcroft; Jeannette Bigler; J Mark FitzGerald; Michael Boedigheimer; Beth E Davis; Clapton Dias; Kevin S Gorski; Lynn Smith; Edgar Bautista; Michael R Comeau; Richard Leigh; Jane R Parnes
Journal:  N Engl J Med       Date:  2014-05-20       Impact factor: 91.245

3.  Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.

Authors:  Joachim B Kunz; Tobias Rausch; Obul R Bandapalli; Juliane Eilers; Paulina Pechanska; Stephanie Schuessele; Yassen Assenov; Adrian M Stütz; Renate Kirschner-Schwabe; Jana Hof; Cornelia Eckert; Arend von Stackelberg; Martin Schrappe; Martin Stanulla; Rolf Koehler; Smadar Avigad; Sarah Elitzur; Rupert Handgretinger; Vladimir Benes; Joachim Weischenfeldt; Jan O Korbel; Martina U Muckenthaler; Andreas E Kulozik
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

4.  Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Deepa Bhojwani; Huining Kang; Naomi P Moskowitz; Dong-Joon Min; Hokyung Lee; Jeffrey W Potter; George Davidson; Cheryl L Willman; Michael J Borowitz; Ilana Belitskaya-Levy; Stephen P Hunger; Elizabeth A Raetz; William L Carroll
Journal:  Blood       Date:  2006-07-15       Impact factor: 22.113

Review 5.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

6.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

7.  Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse.

Authors:  Jason E Farrar; Heather L Schuback; Rhonda E Ries; Daniel Wai; Oliver A Hampton; Lisa R Trevino; Todd A Alonzo; Jaime M Guidry Auvil; Tanja M Davidsen; Patee Gesuwan; Leandro Hermida; Donna M Muzny; Ninad Dewal; Navin Rustagi; Lora R Lewis; Alan S Gamis; David A Wheeler; Malcolm A Smith; Daniela S Gerhard; Soheil Meshinchi
Journal:  Cancer Res       Date:  2016-03-03       Impact factor: 12.701

8.  Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.

Authors:  Maria Morak; Andishe Attarbaschi; Susanna Fischer; Christine Nassimbeni; Reinhard Grausenburger; Stephan Bastelberger; Stefanie Krentz; Gunnar Cario; David Kasper; Klaus Schmitt; Lisa J Russell; Ulrike Pötschger; Martin Stanulla; Conny Eckert; Georg Mann; Oskar A Haas; Renate Panzer-Grümayer
Journal:  Blood       Date:  2012-10-22       Impact factor: 22.113

9.  Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.

Authors:  Brenton G Mar; Lars B Bullinger; Kathleen M McLean; Peter V Grauman; Marian H Harris; Kristen Stevenson; Donna S Neuberg; Amit U Sinha; Stephen E Sallan; Lewis B Silverman; Andrew L Kung; Luca Lo Nigro; Benjamin L Ebert; Scott A Armstrong
Journal:  Nat Commun       Date:  2014-03-24       Impact factor: 14.919

10.  Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.

Authors:  Hamid Ali Nagi Al-Jamal; Siti Asmaa Mat Jusoh; Rosline Hassan; Muhammad Farid Johan
Journal:  BMC Cancer       Date:  2015-11-07       Impact factor: 4.430
View more
  1 in total

1.  Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemia.

Authors:  Coralie Poulard; Hye Na Kim; Mimi Fang; Karina Kruth; Celine Gagnieux; Daniel S Gerke; Deepa Bhojwani; Yong-Mi Kim; Martin Kampmann; Michael R Stallcup; Miles A Pufall
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-07       Impact factor: 11.205
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.